Genesystem
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Genesystem develops and makes molecular diagnostic tools, compact devices, biochips, test kits, and reagents that identify diseases by detecting genetic material, including at the point of care rather than in a central lab.
Its products are designed for ease of use, with reagents built directly into the biochip, and are aimed at clinical and diagnostic customers. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company generates a meaningful share of its revenue from exports. Its core platform supports a range of respiratory-disease test content, which it continues to expand for global distribution.
Summary is AI-generated and may contain errors · figures from DART filings
Genesystem in five facts
What does Genesystem do?
Genesystem develops and makes molecular diagnostic tools, compact devices, biochips, test kits, and reagents that identify diseases by detecting genetic material, including at the point of care rather than in a central lab.
Where is Genesystem listed and in which sector?
Genesystem (Korean name: 진시스템) trades under KRX code 363250 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is Genesystem?
Its market capitalisation was US$26.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Genesystem's latest annual revenue and operating profit?
For fiscal year 2025, Genesystem reported revenue of US$287.8K, an operating loss of US$7.3M and a net loss of US$11.1M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 68.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Attachment amended] Material event report (merger)M&A · Oct 16
- DisclosureOct 15
- Merger decision (subsidiary)M&A · Oct 15
- Material event report (merger)M&A · Oct 15
- Material event report (asset disposal)Oct 12
- Securities issuance results (voluntary)Oct 8
- [Amended] DisclosureSep 30
- Material event report (convertible bonds)
Genesystem disclosed convertible bonds to raise US$4.27M, about 16.4% of its market value.
Capital raise · Sep 30 - [Amended] Material event report (equity acquisition)
Genesystem Co., Ltd. amends its July 30, 2026 report on acquiring all 15,000 shares (100%) of Gyeongbo Electric Co., Ltd. for US$7.39M, revising its future restructuring plan to remove a previously stated specific merger method and purpose and instead describe only a general review of a possible future merger with no finalized structure or schedule.
M&A · Jul 31 · 2 versions - [Amended] Change of largest shareholderOwnership change · Apr 1 · 2 versions
- Securities issuance results (voluntary) (third-party placement)Capital raise · Mar 31
- Securities issuance results (voluntary) (third-party placement)Capital raise · Feb 27
- [Amended] Material event report (rights offering)
Genesystem updated the terms of a private placement (third-party allotment) to raise US$2.09M, about 8.5% of its market value.
Capital raise · Feb 27 - [Amended] Material event report (rights offering)
Genesystem updated the terms of a private placement (third-party allotment) to raise US$2.09M, about 8.5% of its market value.
Capital raise · Feb 27 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Genesystem reported consolidated results for FY2025: revenue of US$264K (−68.4% year on year), an operating loss of US$6.73M and a net loss of US$10.2M.
Earnings · Feb 12 - [Amended] Material event report (rights offering)
Genesystem updated the terms of a private placement (third-party allotment) to raise US$2.06M, about 8.5% of its market value.
Capital raise · Feb 11 - [Amended] Material event report (rights offering)
Genesystem updated the terms of a private placement (third-party allotment) to raise US$2.06M, about 8.5% of its market value.
Capital raise · Feb 11 - Agreement on change of control signed
Genesystem's controlling stake is set to change hands from an individual to an investment partnership, in a deal worth US$4.11M.
Ownership change · Feb 10 - Material event report (rights offering)
Genesystem disclosed a private placement (third-party allotment) to raise US$2.06M, about 8.5% of its market value.
Capital raise · Feb 10 - Material event report (rights offering)
Genesystem disclosed a private placement (third-party allotment) to raise US$2.06M, about 8.5% of its market value.
Capital raise · Feb 10